Mest Hans-Juergen
Lilly Forschung GmbH, Lilly Research Laboratories, Essener Bogen 7, 22419 Hamburg, Germany.
Curr Opin Investig Drugs. 2006 Apr;7(4):338-43.
Incretin levels approach normal physiological values following treatment with dipeptidyl peptidase (DPP)-IV inhibitors. This is in contrast to incretin levels resulting from the exogenous administration of glucagon-like peptide (GLP)-1 and its analogs, which can reach super-physiological values. This review describes the role of DPP-IV inhibitors as incretin enhancers in the regulation of glucose homeostasis in type 2 diabetic patients. The roles of incretins and the effect of DPP-IV on their actions are described, as are new therapeutic interventions based on the restoration of impaired incretin secretion in type 2 diabetic patients and obese individuals. In addition, the relevance of DPP-IV inhibition for weight control, its potential influence on beta-cell mass, and possible new indications are discussed, as are the implications of the currently available clinical data.
使用二肽基肽酶（DPP）-IV抑制剂治疗后，肠促胰岛素水平接近正常生理值。这与外源性给予胰高血糖素样肽（GLP）-1及其类似物所导致的肠促胰岛素水平形成对比，后者可达到超生理值。本综述描述了DPP-IV抑制剂作为肠促胰岛素增强剂在2型糖尿病患者葡萄糖稳态调节中的作用。文中阐述了肠促胰岛素的作用以及DPP-IV对其作用的影响，还介绍了基于恢复2型糖尿病患者和肥胖个体受损肠促胰岛素分泌的新治疗干预措施。此外，还讨论了DPP-IV抑制对体重控制的相关性、其对β细胞量的潜在影响以及可能的新适应症，以及现有临床数据的意义。
